# Sequential Intensive Chemotherapy Followed by RIC for Refractory and Relapse ALL

> **NCT02766868** · PHASE2 · UNKNOWN · sponsor: **Shanghai Jiao Tong University School of Medicine** · enrollment: 20 (estimated)

## Conditions studied

- Lymphoblastic Leukemia, Acute, Adult

## Interventions

- **DRUG:** FACE-Flu/Bu/Cy

## Key facts

- **NCT ID:** NCT02766868
- **Lead sponsor:** Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-01
- **Primary completion:** 2019-01
- **Final completion:** 2019-07
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2016-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02766868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02766868, "Sequential Intensive Chemotherapy Followed by RIC for Refractory and Relapse ALL". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02766868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*